Stromal fibrin shapes immune infiltration landscape of pancreatic ductal adenocarcinoma

被引:0
|
作者
Karim, Mazharul [1 ,2 ]
Hasan, Md Mahedi [3 ]
Kim, Seung Hyun [4 ]
Azam, Zulfikar [1 ]
Wahab, Riajul [1 ]
Islam, Tamanna [3 ]
Alam, Farzana [5 ]
Kim, Yun-Jae [6 ]
Bae, Dong-Jun [6 ]
Roy, Sourav [7 ]
Grippo, Paul [8 ]
Bishehsari, Faraz [9 ,10 ]
Choi, Jeong Uk [4 ]
Al-Hilal, Taslim A. [1 ,3 ]
机构
[1] Univ Utah, Dept Mol Pharmaceut, Salt Lake City, UT 84112 USA
[2] Univ Texas El Paso, Sch Pharm, Dept Pharmaceut Sci, El Paso, TX 79968 USA
[3] Univ Utah, Dept Biomed Engn, Salt Lake City, UT USA
[4] Kyung Hee Univ, Coll Pharm, Seoul 02453, South Korea
[5] Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT USA
[6] PrismCDX, Hwaseong Si, Gyeonggi Do, South Korea
[7] Univ Texas El Paso, Coll Sci, Dept Biol Sci, El Paso, TX 79968 USA
[8] Univ Illinois, Dept Med, Chicago, IL USA
[9] Univ Texas Houston, Gastroenterol Res Ctr, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA
[10] UTHlth Houston, MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX USA
关键词
USA; Pancreatic cancer; Fibrin; Tumor stroma; Immunomodulation; TUMOR-ASSOCIATED MACROPHAGES; CELL;
D O I
10.1016/j.biomaterials.2025.123280
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
In pancreatic ductal adenocarcinoma (PDAC), in-situ coagulation creates a thrombotic, crosslinked fibrin (xfibrin)-rich tumor stroma (FibTS), whose impact on immune cell behavior remains unclear. We aimed to elucidate how FibTS in PDAC regulates immune cell infiltration, polarization, and crosstalk that favors immunosuppressive microenvironment and tumor growth. We assessed the spatial distribution of immune cells by multiplex immunostaining of human PDAC tissues, along with novel bioengineering and mouse tumor models. We investigated how FibTS influences the infiltration of tumor-associated macrophage (TAM) and T-cell subtypes and identified two distinct variants of PDAC, fibrin-high (Fibhi) and fibrin-low (Fiblow). Our findings reveal that PDAC cells secrete fibrinogen and thrombin to form FibTS, which acts as a physical barrier and biochemical niche that restricts CD8+ T-cell and TAM penetration into the tumor. The FibTS impeded immune cell penetration from the tumor stroma into the tumor parenchyma. Selective inhibition of FibTS formation by genetic and pharmacological tools altered the infiltration patterns of CD8+ T-cells and TAMs, decelerating PDAC growth. This study demonstrates that the barrier function of FibTS is crucial for immune evasion, particularly against macrophage and T-cell activity, presenting a potential therapeutic strategy to reshape the immune landscape within PDAC and slow tumor progression.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma
    Ali, Ahmad
    Chianese, Ugo
    Papulino, Chiara
    Toraldo, Antonella
    Abakar, Mawada Elmagboul Abdalla
    Passaro, Eugenia
    Cennamo, Rosario
    Del Gaudio, Nunzio
    Altucci, Lucia
    Benedetti, Rosaria
    CANCERS, 2022, 14 (15)
  • [22] Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
    Bailey, Peter
    Chang, David K.
    Forget, Marie-Andree
    San Lucas, Francis A.
    Alvarez, Hector A.
    Haymaker, Cara
    Chattopadhyay, Chandrani
    Kim, Sun-Hee
    Ekmekcioglu, Suhendan
    Grimm, Elizabeth A.
    Biankin, Andrew V.
    Hwu, Patrick
    Maitra, Anirban
    Roszik, Jason
    SCIENTIFIC REPORTS, 2016, 6
  • [23] Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma
    Liu, Peiyi
    Jacques, Juliette
    Hwang, Chang-Il
    EPIGENOMES, 2024, 8 (04)
  • [24] Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma
    Roy, Shikha
    Singh, Amar Pratap
    Gupta, Dinesh
    HELIYON, 2021, 7 (01)
  • [25] Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
    Peter Bailey
    David K. Chang
    Marie-Andrée Forget
    Francis A. San Lucas
    Hector A. Alvarez
    Cara Haymaker
    Chandrani Chattopadhyay
    Sun-Hee Kim
    Suhendan Ekmekcioglu
    Elizabeth A. Grimm
    Andrew V. Biankin
    Patrick Hwu
    Anirban Maitra
    Jason Roszik
    Scientific Reports, 6
  • [26] Unconvering the hidden immunosuppressive landscape in pancreatic ductal adenocarcinoma
    Qian, Guhan
    Zhang, Hongrong
    Knott, Aine
    Zettervall, Jon
    Stromnes, Ingunn
    Provenzano, Paolo
    CANCER RESEARCH, 2024, 84 (02)
  • [27] Deciphering the role of CREB1 in shaping the tumor immune landscape of pancreatic ductal adenocarcinoma
    Mehra, Siddharth
    Garrido, Vanessa
    Singh, Samara
    Silva, Iago D.
    Nivelo, Luis Alberto
    Bianchi, Anna
    Modi, Shrey
    Zhou, Zhiqun
    Dosch, Austin
    Deshpande, Nilesh
    Srinivasan, Supriya
    Rafie, Christine
    Ogobuiro, Ifeanyichukwu
    Chen, Xi
    Villarino, Alejandro
    Datta, Jashodeep
    Merchant, Nipun
    Nagathihalli, Nagaraj
    CANCER RESEARCH, 2022, 82 (12)
  • [28] A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact.
    Guerrero, Jose Antonio Lopez
    Melian-Sosa, Marcos
    Martinez, Zoraida Andreu
    Lopez-Reig, Raquel
    Fernandez-Serra, Antonio
    Machado, Isidro
    Yaya-Tur, Ricardo
    Garcia-Flores, Maria
    Trallero-Anoro, Marta
    Martinez-Lapiedra, Carmen
    de Juan, Fernando Martinez
    Ramirez-Calvo, Marta
    Mazcunan-Vitiello, Tania
    Carretero-Hinojosa, Patricia
    Estevan, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 681 - 681
  • [29] Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma
    Liu, Xiaomeng
    Liu, Jiang
    Xu, Jin
    Zhang, Bo
    Wei, Miaoyan
    Li, Jialin
    Xu, Hang
    Yu, Xianjun
    Wang, Wei
    Shi, Si
    TRANSLATIONAL ONCOLOGY, 2023, 27
  • [30] Gasdermin C as a potential prognostic biomarker and its correlation with immune infiltration in pancreatic ductal adenocarcinoma.
    Xia, Xianghou
    Yu, Yang
    Yang, Hongjian
    Zou, Dehong
    Wang, Canming
    Hu, Jiejie
    Mao, Jiefei
    Cai, Xixi
    Yin, Wenjuan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)